Author:
Malhotra Charvi,Kullar Peter
Abstract
Mitochondrial hearing loss (MHL) arises from mutations in mitochondrial DNA (mtDNA) or in nuclear genes coding for mitochondrial proteins, which impair inner ear function resulting in hearing loss. Diagnosis of MHL requires a comprehensive evaluation, including genetic tests, clinical assessments, and audiological examination. Treatment options for MHL are limited, with supportive measures to enhance communication and restore hearing function being the primary options. Ongoing research is investigating new therapies that target mitochondrial dysfunction and regenerative techniques to restore hearing function. It is crucial to understand the underlying mechanisms of MHL and develop effective interventions to mitigate its negative impact.
Reference20 articles.
1. Fancello V, Fancello G, Palma S, Monzani D, Genovese E, Bianchini C, et al. The Role of Primary Mitochondrial Disorders in Hearing Impairment: An Overview. Medicina (Kaunas). 19 Mar 2023;(3):608. doi: 10.3390/medicina59030608. PMID: 36984609; PMCID: PMC10058207
2. Kang J, Wang C, Lu Y. Mitochondrial-targeted therapies for hearing loss: A mini-review. Frontiers in Cellular Neuroscience. 2021;:674768
3. Liu Y, Xue J, Zhao D, Chen L, Yuan Y, Wang Z. Audiological evaluation in Chinese patients with mitochondrial encephalomyopathies. Chinese Medical Journal. 2014;(12):2304-2309
4. Smith RJ, Bale JF Jr, White KR. Sensorineural hearing loss in children. Lancet. 2005;(9462):879-890. DOI: 10.1016/S0140-6736(05)71047-3
5. Fernandez-Vizarra E, Enriquez JA, Perez-Martos A, Montoya J, Fernandez-Silva P. Tissue-specific differences in mitochondrial activity and biogenesis. Mitochondrion. 2011;(1):207-213. DOI: 10.1016/j.mito.2010.09.011